While Edgewise Therapeutics Inc has underperformed by -0.73%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EWTX rose by 35.76%, with highs and lows ranging from $38.12 to $14.90, whereas the simple moving average fell by -8.53% in the last 200 days.
On March 07, 2025, Scotiabank started tracking Edgewise Therapeutics Inc (NASDAQ: EWTX) recommending Sector Outperform. A report published by Stifel on January 22, 2025, Initiated its previous ‘Hold’ rating for EWTX. Evercore ISI also rated EWTX shares as ‘Outperform’, setting a target price of $45 on the company’s shares in an initiating report dated November 22, 2024. Piper Sandler Initiated an Overweight rating on March 07, 2024, and assigned a price target of $48. Truist initiated its ‘Buy’ rating for EWTX, as published in its report on May 01, 2023. Goldman’s report from August 25, 2022 suggests a price prediction of $5 for EWTX shares, giving the stock a ‘Sell’ rating. RBC Capital Mkts also rated the stock as ‘Outperform’.
Analysis of Edgewise Therapeutics Inc (EWTX)
Edgewise Therapeutics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -34.40% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 19.93, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and EWTX has an average volume of 1.16M. On a monthly basis, the volatility of the stock is set at 8.77%, whereas on a weekly basis, it is put at 8.90%, with a loss of -1.44% over the past seven days. Furthermore, long-term investors anticipate a median target price of $47.44, showing growth from the present price of $23.27, which can serve as yet another indication of whether EWTX is worth investing in or should be passed over.
How Do You Analyze Edgewise Therapeutics Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 29.38%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 78.78% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
EWTX shares are owned by institutional investors to the tune of 78.78% at present.
